These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 3161533)
41. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111 [TBL] [Abstract][Full Text] [Related]
42. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723 [TBL] [Abstract][Full Text] [Related]
43. Deoxyribonucleic acid (DNA) content of primary carcinoma and response to endocrine or cytotoxic drug therapies in patients with advanced breast cancer. Mitchell I; Deshpande N; Millis R; Rubens RD Eur J Surg Oncol; 1985 Sep; 11(3):251-6. PubMed ID: 4029405 [TBL] [Abstract][Full Text] [Related]
44. Tamoxifen and partial oestrogen agonism in postmenopausal women. Miodrag A; Ekelund P; Burton R; Castleden CM Age Ageing; 1991 Jan; 20(1):52-4. PubMed ID: 1903020 [TBL] [Abstract][Full Text] [Related]
45. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. Buchholz TA; Tucker SL; Erwin J; Mathur D; Strom EA; McNeese MD; Hortobagyi GN; Cristofanilli M; Esteva FJ; Newman L; Singletary SE; Buzdar AU; Hunt KK J Clin Oncol; 2001 Apr; 19(8):2240-6. PubMed ID: 11304777 [TBL] [Abstract][Full Text] [Related]
46. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
47. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Rubens RD; Tinson CL; Coleman RE; Knight RK; Tong D; Winter PJ; North WR Br J Cancer; 1988 Nov; 58(5):626-30. PubMed ID: 3219274 [TBL] [Abstract][Full Text] [Related]
48. DES versus tamoxifen in advanced breast cancer. N Engl J Med; 1981 Apr; 304(17):1041-3. PubMed ID: 7010171 [No Abstract] [Full Text] [Related]
50. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513 [TBL] [Abstract][Full Text] [Related]
51. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Michaud LB; Buzdar AU Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521 [TBL] [Abstract][Full Text] [Related]
52. Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells. Hochner-Celnikier D; Greenfield C; Finci-Yeheskel Z; Milwidsky A; Gutman A; Goldman-Wohl D; Yagel S; Mayer M Mol Hum Reprod; 1997 Dec; 3(12):1019-27. PubMed ID: 9464846 [TBL] [Abstract][Full Text] [Related]
53. Tamoxifen for early breast cancer. Early Breast Cancer Trialists' Collaborative Group Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694 [TBL] [Abstract][Full Text] [Related]
54. The place of chemotherapy in the treatment of early breast cancer. Buzdar A Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784 [TBL] [Abstract][Full Text] [Related]
55. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches. Nobert GS; Kraak MM; Crawford S Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071 [TBL] [Abstract][Full Text] [Related]
56. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323 [TBL] [Abstract][Full Text] [Related]
57. The curability of breast cancer and the treatment of advanced disease. Guarneri V; Conte PF Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948 [TBL] [Abstract][Full Text] [Related]
58. Activity and androgenic control of glycolytic enzymes in the epididymis and epididymal spermatozoa of the rat. Brooks DE Biochem J; 1976 Jun; 156(3):527-37. PubMed ID: 182156 [TBL] [Abstract][Full Text] [Related]
59. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. Boccardo F; Guglielmini P; Parodi A; Rubagotti A Breast Cancer Res Treat; 2011 Apr; 126(3):653-61. PubMed ID: 21347647 [TBL] [Abstract][Full Text] [Related]
60. Adjuvant treatment for breast cancer in the elderly. Marchei P; Bianco V; Pignatelli E; Chiodini S; Santini D; Carico E; Marchei M; Vecchione A Anticancer Res; 1996; 16(2):911-3. PubMed ID: 8687150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]